Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

331
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital quantum magnetism on a trapped-ion quantum computer.

Nature·2026
Same author

Probing non-equilibrium topological order on a quantum processor.

Nature·2025
Same author

Visualizing dynamics of charges and strings in (2 + 1)D lattice gauge theories.

Nature·2025
Same author

PTV Margins in MR-guided and Beam-gated SBRT of Liver Metastases: GTV Dose Escalation Can Reduce the Required PTV.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

REMIT: Reirradiation of Diffuse Midline Glioma Patients -A Nordic Society of Paediatric Haematology and Oncology Feasibility Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Acute toxicities in proton therapy for head and neck cancer - A matched analysis of the DAHANCA 35 feasibility study.

Clinical and translational radiation oncology·2024

Related Experiment Video

Updated: Jun 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Early Mortality After Curative-intent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer-A

K H Jensen1, G Persson2, M Pøhl1

  • 1Rigshospitalet, Department of Oncology, Copenhagen, Denmark.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|September 21, 2024
PubMed
Summary

Early mortality in locally advanced non-small cell lung cancer (LA-NSCLC) patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) is 10% and occurs uniformly. Age, performance status, and male sex increase risk, but no specific high-risk period exists.

Keywords:
Early mortalityNSCLCRadiotherapy

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K

Related Experiment Videos

Last Updated: Jun 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.2K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Public Health

Background:

  • Locally advanced non-small cell lung cancer (LA-NSCLC) treatment with curative-intent radiotherapy (RT) or chemoradiotherapy (CRT) has significant toxicity.
  • Approximately 50% of LA-NSCLC patients die within two years, necessitating better understanding of early mortality.
  • Identifying risk factors for early death is crucial for patient selection and supportive care.

Purpose of the Study:

  • To investigate the incidence, temporal distribution, and risk factors of early mortality in LA-NSCLC patients undergoing RT/CRT.
  • To determine if a specific high-risk period for mortality exists post-treatment.
  • To identify clinical and demographic predictors of early death.

Main Methods:

  • Population-based nationwide cohort study of 1742 patients with stage II-III NSCLC treated with RT/CRT in Denmark (2010-2017).
  • Exclusion of patients receiving neoadjuvant/adjuvant RT/CRT or stereotactic body radiation therapy.
  • Definition of early mortality as all-cause death within 180 days of RT/CRT initiation; multivariable logistic regression analysis.

Main Results:

  • The overall early mortality rate was 10%.
  • Deaths were uniformly distributed throughout the first year post-treatment, with no identifiable high-risk period.
  • Increasing age, poorer performance status, and male sex were associated with increased early mortality risk; unspecified histology also showed increased risk.
  • Charlson Comorbidity Index (CCI), TNM stage, and treatment period did not significantly impact early mortality risk.

Conclusions:

  • No specific high-risk period for early mortality was identified in LA-NSCLC patients treated with RT/CRT.
  • Early mortality was not significantly associated with the Charlson Comorbidity Index (CCI).
  • Further research is needed to identify effective tools for comorbidity assessment and risk stratification in this patient population.